The general characteristics of anemia and the distinguishing features of hemolytic, hemorrhagic, hypoproliferative, maturation abnormality, and iron-deficiency anemias are described. Hemolytic anemias are differentiated initially from hemorrhagic anemias by excluding hemorrhage on clinical, necropsy, or histologic examination. Next, they are distinguished from the remaining types of anemia on the basis of higher reticulocyte counts or, in some instances, by the very rapid rate of decline of the PCV. Hemolytic anemias are distinguished from each other on the basis of incidence and the presence or absence of a dose-response (idiosyncratic vs toxic) and by the cause of hemolysis (oxidative, nonoxidative, or immune-mediated). Hemorrhagic anemias are subclassified on the basis of single-and multiple-site hemorrhage. The causes of multiple-site hemorrhage (hemostasis dysfunction) are established by firstand second-line tests, the type of bleeding, clinical data, and the information gained from an evaluation of the structure, activity, and metabolism of the compound.
INTRODUCTION
The objectives of this paper are to describe the salient characteristics of hemolytic and hemorrhagic (regenerative) anemias and to provide a framework for differentiating the hemolytic and hemorrhagic anemias from each other and from the hypoproliferative, maturation abnormality, and iron-deficiency (nonregenerative) anemias. This framework (scheme) is summarized in Fig. 1 .
GENERAL CHARACTERISTICS OF ANEMIA
Anemia is defined as a decrease in the oxygencarrying capacity of the blood due to a reduction in numbers of circulating red cells. Laboratory diagnosis is based on detecting a reduction in packed cell volume (PCV), hemoglobin (Hgb) concentration, or red blood cell (RBC) count below the reference range for the particular species. In toxicology studies, it is advantageous to classify anemia into 5 etiologic categories: hemolytic, hemorrhagic, hypoproliferative, maturation abnormality, and iron deficiency.
The causes of hemolytic and hemorrhagic anemias are found in the erythrocytes themselves or in the peripheral blood rather than in the bone marrow ( 1, 2) . Hemolytic and hemorrhagic anemias are regenerative due to a compensatory increase in erythropoiesis in the bone marrow. The spleen is also frequently involved in the regenerative response through extramedullary hematopoiesis. Changes associated with the erythropoietic response are detectable in the peripheral blood after a lapse of [3] [4] [5] days (3). These changes include anisocytosis, polychromasia, reticulocytosis, increased mean cell volume (MCV), increased or normal mean cell hemoglobin (MCH), decreased mean cell hemoglobin concentration (MCHC), and bone marrow erythroid hyperplasia. The regenerative response is generally more pronounced in hemolytic than in hemorrhagic anemia because iron is conserved for erythropoiesis in the former. This results in higher reticulocyte counts in hemolytic than in hemorrhagic anemias. Hemolytic and hemorrhagic anemias of less than 3-5 days duration show little or no evidence of a bone marrow regenerative response in the peripheral blood (too early) and therefore could be diagnosed as nonregenerative anemias if only peripheral blood is examined. Bone marrow examination, however, reveals nascent erythroid hyperplasia. Hypoproliferative and maturation abnormality anemias are characterized by reduced production of erythrocytes in the bone marrow as a result of abnormalities in erythroid precursor cell proliferation, differentiation, or maturation. These anemias are also called nonregenerative anemias since the etiology is related to a bone marrow response that is inadequate for the degree of anemia (2) . Potential causes of hypoproliferative anemia in toxicology studies are marrow damage (e.g., stem cell cytostasis, cytolysis due to oncolytic and/or antiviral agents), chronic extramyeloid inflammation, or intramarrow hemolysis. Agents that inhibit normal nuclear maturation by interfering with DNA synthesis (e.g., folate antagonists) are a common cause of maturation abnormality anemia in toxicology studies.
Less commonly, agents that interfere with hemoglobin synthesis are encountered. The majority of hypoproliferative anemias have the classical features of a nonregenerative anemia: decreased PCV, normal red cell indices (MCV, MCH, and MCHC), normal or decreased reticulocyte count, bone marrow erythroid hypoplasia of variable severity, and a preponderance of normochromic normocytic erythrocytes on the blood smear. Hypoproliferative anemia due to intramarrow hemolysis (nonclassical hypoproliferative anemia) is distinctly different. It is characterized by a nonregenerative or mildly regenerative hemogram and the triad of normoblastoid erythroid hyperplasia, erythrophagocytosis, and hemosiderosis in the bone marrow. Maturation abnormality anemia, associated with inhibition of nuclear maturation, is differentiated on the basis of increased numbers of macrocytic normochromic erythrocytes in the peripheral blood, and megaloblastoid erythropoiesis and increased death of erythroid precursors in the bone marrow.
Rarely, iron-deficiency anemia occurs in toxicology studies. Irrespective of cause-hemorrhage, decreased absorption, or increased chelation-irondeficiency anemia is difficult to diagnose unless it presents in the classical microcytic hypochromic form (significantly decreased PCV, MCV, MCH, and MCHC). If iron deficiency presents as a regenerative anemia (early-stage iron-deficiency anemia), determination of serum iron, total iron-binding capacity, or serum ferritin may be useful to establish the diagnosis in the living animal. In dead animals, demonstrating the absence of stainable iron stores in histologic sections of bone marrow (all species) or spleen (rats) is diagnostic.
HEMOLYTIC ANEMIA
Features
The defining characteristic of hemolytic anemia is a shortened RBC life span. RBC are either lysed in the circulation (intravascular hemolysis) or phagocytosed by the mononuclear macrophages of the reticuloendothelial system (RE phagocytosis) in the bone marrow, spleen, or liver (extravascular hemolysis).
Intravascular Hemolysis
Intravascular hemolysis is characterized by hemoglobinemia, hemoglobinuria, decreases in serum haptoglobin, and increases in hemosiderin in the urine. Visible hemoglobinemia and hemoglobinuria are not detected unless the hemolysis is severe. In mild cases, invisible hemoglobinemia may be detected by the plasma-free hemoglobin assay or by demonstrating a reduction in serum haptoglobin. Hemosiderin is also increased in the proximal convoluted tubular epithelium of the kidney. It is readily demonstrated in urine sediment or in histologic sections of kidney utilizing a Prussian blue stain. However, Prussian blue staining may be of limited utility in the mouse since positive staining is observed in the kidneys of some strains (e.g., CD-1 I mice) in the absence of hemolytic anemia (unpublished observations).
Extravascular Hemolysis
Extravascular hemolysis (RE phagocytosis) is characterized by the absence of hemoglobinemia and hemoglobinuria. Decreased serum haptoglobin and hemosiderinuria are not seen. There usually are increases in the size and weight of the spleen and in the amount of hemosiderin in splenic macrophages.
Hemosiderin is also increased in bone marrow macrophages and less frequently in the Kupffer cells of the liver.
Causes
Likely causes of hemolytic anemia in toxicology studies include oxidation of sulfhydryl groups in hemoglobin and/or erythrocyte membranes, nonoxidative (chemical and/or fragmentation) injury of erythrocytes, and anti-RBC antibodies of the IgG class (unpublished observations). Each cause, with the exception of IgG anti-RBC antibodies, may result in extravascular or intravascular hemolysis or both. In a given case, one form of hemolysis usually predominates. Extravascular (RE phagocytosis) hemolysis appears to be more common than intravascular hemolysis in toxicology studies (unpublished observations).
Idiosyncratic/Toxic Hemolytic Anemia
Hemolytic anemias may also be classified as either idiosyncratic or toxic. Idiosyncratic hemolytic anemias affect 1 or few animals in a study, are most frequently encountered in dogs, and have many of the features of an immune-mediated process-rapid clearance of erythrocytes from the circulation, spherocytosis and agglutination of erythrocytes or peripheral blood smears, and shortened induction time of the anemia on reexposure to the compound. The direct antiglobulin test may be positive (unpublished observations). The reticulocyte count is either normal or increased. Neutropenia and/or thrombocytopenia may be present. Although a classical dose-response relationship is not evident, affected animals are usually from the higher dose groups in a study and onset rarely occurs during the first month (unpublished observations). Nonimmune-mediated idiosyncratic hemolytic anemia is rare. If it is suspected, it should be distinguished from hemolytic anemia involving a few individual animals either as a secondary manifestation of a primary compound toxicity or unrelated to compound administration.
Toxic hemolytic (dose-related) anemia is due to oxidative or nonoxidative injury to the erythrocyte; rarely is fragmentation injury a cause of nonoxidative toxic hemolytic anemia. Severity of hemolysis increases with increasing dosage so that anemia is present in the majority of animals in the higher dose groups. Onset is quicker than idiosyncratic hemolytic anemia. Oxidative or nonoxidative injury to erythrocytes may result in intravascular hemolysis, extravascular hemolysis, or both. Extravascular hemolysis appears to be more common in oxidative injury (unpublished observations). One or more of the following are detected on examination of blood smears in cases of oxidative injury: eccentrocytes, bite cells, erythrocytes containing Heinz bodies, and irregularly contracted (1) densely staining (1, 4) erythrocytes (pyknocytes). Heinz bodies may be infrequent or absent. Methemoglobin is frequently increased (unpublished observations) because many agents that oxidize the sulfhydryl groups in hemoglobin and in the erythrocyte membrane also oxidize the ferrous iron of heme to the ferric form.
DIAGNOSIS OF HEMOLYTIC ANEMIA

Rate/Magnitude o,f PCV Decline
The first step in the diagnosis of hemolytic anemia is to exclude hemorrhage by clinical, necropsy, or laboratory examination. Next, the severity and the rate of decline of the PCV is assessed. If the PCV in a dog declines by half in 30 days or less-rapid decline (Fig. 1) -an unequivocal diagnosis of hemolytic anemia can be made. Thirty days is approximately one-quarter of the RBC life span in a dog; it takes approximately 60 days for the PCV to decline by half in the dog if erythropoiesis ceases completely. Good approximations of one-quarter of the RBC life spans in monkeys and in rats and rab-bits are 30 and 10 days, respectively. Severe reductions in the PCV in the absence of a knowledge of the time course are less easy to diagnose. In addition to hemolytic anemia, other causes must be considered.
If the reduction in the PCV is moderate-PCV decreased to between 20 and 29% in dogs (5)-or if the rate of decline is gradual, the likely possibilities are hemolytic anemia, hypoproliferative anemia, maturation abnormality anemia, and iron-deficiency anemia (regenerative form). The absolute reticulocyte count, or the reticulocyte production index (RPI), which are measures of effective production of red cells by the bone marrow, separate hemolytic anemia from the other 3 types since compensatory increases in RBC production are greater in hemolytic anemia than in other anemias.
Absolute Reticulocyte CountlReticulocyte Production Index
The absolute reticulocyte count is calculated by multiplying the reticulocyte count (%) by the RBC count (millions/~1) and expressing the result in thousands/ill. If hemorrhage is excluded, a 3-5-fold or greater increase in absolute reticulocyte count is suggestive of hemolytic anemia in toxicology studies (unpublished observations).
The RPI corrects the reticulocyte count both for the degree of anemia and for the differences in reticulocyte maturation times that occur at different PCVs. Reticulocyte maturation times are inversely proportional to the PCV. In humans, these times are 1.0, 1.5, 2.0, and 2.5 days for PCVs of 45, 35, 25, and 15, respectively (3) . These times have also been used clinically in the dog (5) . They may also apply to primate species since primate hematopoiesis is quite similar to that of humans. For rabbits and for rodent species, it is more appropriate to use absolute reticulocyte counts, because data on reticulocyte maturation times are not available. It has become customary in clinical veterinary medicine to use 45 as the average PCV in calculating the RPI in the dog (5) . Thus, for an anemic dog with a reticulocyte count of 6% and a PCV of 25%, the RPI is calculated as follows:
In the preceding example, the RPI of 1.7 represents a rate of effective erythropoiesis that is ap- FIG. 1. -Scheme for the differential diagnosis of anemia in toxicology studies. 
Abbreviations: APTT = activated partial thromboplastin time; N = normal; PLT = platelet count; PT = prothrombin time. a Pattern varies with severity and/or cause of disorder. proximately 4-fold less than that suggested by the reticulocyte count. In clinical veterinary medicine, an RPI in the dog greater than or equal to 3 suggests hemolytic anemia rather than external hemorrhage (5) . In toxicology studies, an RPI in the dog greater than or equal to 2 is frequently associated with hemolytic anemia (unpublished observations). In humans, an RPI less than or equal to 2 suggests hypoproliferative, iron-deficiency, or maturation abnormality anemia (3) . This also appears to be the case for the dog in toxicology studies (unpublished observations).
HEMORRHAGIC ANEMIA Hemorrhagic anemia may be acute (2-3 days), subchronic (3-10 days), or chronic (10 days plus) in duration. Acute hemorrhage is characterized by consistent reductions in PCV, inconsistent decreases in platelet counts and plasma protein concentrations, and the absence of a regenerative (bone marrow) response. In subchronic hemorrhage, there is evidence of a regenerative response, namely, anisocytosis, polychromasia, reticulocytosis, and bone marrow erythroid hyperplasia. The platelet count and the plasma protein concentration are inconsistently increased and decreased, respectively. Chronic hemorrhage is quite variable in presentation. Depending on duration and severity, it may present as a regenerative, nonregenerative, or iron-deficiency anemia.
DIAGNOSIS OF HEMORRHAGIC ANEMIA
Nature and Cause of Hemorrhage
The initial steps are to determine the severity, location, duration, and cause of the hemorrhage underlying the anemia. Severity and location are established in live animals from an evaluation of the history, clinical observations, and clinical pathology data and by the judicious utilization of tests that localize the site of hemorrhage (e.g., fecal and urine occult blood determinations) and gastroscopic and ophthalmologic examinations. Careful gross and microscopic pathological examination will provide the same information in dead animals. Duration is established from the history and by determining which pattern of hemorrhage -acute, subchronic, or chronic-is compatible with the clinical pathology data.
To establish the cause of hemorrhage, it is important to ascertain whether bleeding is occurring from single or multiple sites (Fig. 1 ) and to assess the type of bleeding. Hemorrhage from multiple sites suggests a disturbance in hemostatic function (2) . The type of bleeding provides insight into the underlying mechanism. Hematomas and extravasations are more likely to occur with perturbations of coagulation and fibrinogenolysis, whereas petechiae and ecchymoses suggest thrombocytopenia or disturbances in platelet function. Enhanced fibrinogenolysis, impaired platelet aggregation, and single or multiple coagulation factor deficiency and/or inhibition are examples of disturbances in hemostatic function that are likely to cause clinical hemorrhage in toxicology studies. Thrombocytopenic bleeding and bleeding as a result of vessel wall injury are uncommon causes of clinical hemorrhage in toxicology studies (unpublished observations).
Hemostasis Disorders
A 2-tier approach consisting of first-and secondline tests is recommended to determine the cause of bleeding when hemostatic dysfunction is suspected. First-line tests are prothrombin time, activated partial thromboplastin time, and platelet count. Second-line tests consist of 1 or more of the following: bleeding time, platelet aggregation, thrombin clot time (TCT), fibrinogen (FBGN) concentration, specific coagulation factor assays, fibrin(ogen) degradation products (FDP), alpha-2 antiplasmin, and plasminogen (PLGN). First-line tests either establish the cause of a bleeding diathesis, coagulation factor deficiency versus thrombocytopenia, or identify the degree to which coagulation factors, platelets, or fibrinogenolysis contribute. If a definitive diagnosis cannot be established from the results of first-line tests, a judicious selection of 1 or more second-line tests should be made. This selection is based on an assessment of the type and incidence of the hemorrhage and on an evaluation of the structure, activity, and metabolism of the compound.
Classical patterns of results of first-line tests in several disorders of hemostasis are shown in Table  I . The diagnostic criteria of deficiency and/or inhibition of factor VII or VIII are readily apparent from the table. Vitamin K deficiency and/or inhibition are differentiated from thrombin inhibition by confirming decreased activities of at least 2 of the vitamin K-dependent coagulation factors (II, VII, IX, and X). Alternatively, thrombin inhibition is distinguished from vitamin K deficiency and/or inhibition on the basis of a prolonged TCT.
Disseminated intravascular coagulation (DIC) and fibrinogenolysis are not readily distinguished by firstline tests unless thrombocytopenia is present (Table  I ). FDP and FBGN (second-line tests) are not helpful in differential diagnosis, because they are increased and decreased, respectively, in both conditions. Helpful distinguishing features of DIC are its low incidence and lack of a dose-response relationship. Fibrinogenolysis, on the other hand, usually occurs in a dose-responsive fashion. Since it is frequently a sequel to administration of plasminogen activators, it is not surprising that dose-related reductions in PLGN are also observed.
Thrombocytopenia and impaired platelet aggregation are distinguished from each other by the decreased platelet count in the former (Table I) and by diminished in vitro platelet aggregation in the latter in response to specific agonists (e.g., ADP, arachidonic acid, or platelet activating factor).
